An observational study in PORTs/Peripheral IVs Complication Rates, sponsored by C. R. Bard. Completed at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2016-06-08.
Sponsored by C. R. Bard · Observational
This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 300 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →C. R. Bard is the lead sponsor of 113 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
All subjects who are currently undergoing or has had infusional cancer therapy (solid tumor or hematologic) through a Bard PORT with a distally-valved catheter/open-ended catheter or infusion through a Peripheral IV
Exclusion Criteria:
Subjects receiving chemotherapy through a port
Subjects receiving chemotherapy through a peripheral IV
The rate of adverse events in subjects undergoing chemotherapy administration through PORTs and PIVs.
Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications
Time frame: Through end of chemotherapy, up to 3 years
The average number of accesses during course of treatment (i.e. - chemotherapy administration, CTs, blood draws, TPN, etc.)
Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications
Time frame: Through end of chemotherapy, up to 3 years
The rate of Vascular Access Device conversion from Peripheral IV to PORT
Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications
Time frame: Through end of chemotherapy, up to 3 years
The average time of vascular access device conversion from Peripheral IV to PORT
Subjects medical records will be retrospectively reviewed from present day back to January 1, 2008 to assess for complications
Time frame: Through end of chemotherapy, up to 3 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
C. R. Bard